Price Alert

Royalty Pharma (RPRX)

NASDAQ: RPRX · Real-Time Price · USD

36.58

0.58 (1.61%)

At close: Aug 20, 2025, 12:48 PM

Royalty Pharma Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Cash & Equivalents	631.91M	1.09B	929.03M	950.05M	1.76B	843M	477.01M	936.45M	2.17B	1.98B	1.71B	991.63M	2.11B	1.79B	1.54B	1.8B	1.14B	708.81M
Short-Term Investments	856.14M	728.66M	841.97M	814.27M	788.6M	689.48M	756.74M	747.46M	735.01M	612.52M	717.04M	1.23B	1.29B	1.12B	1.26B	892.51M	1.51B	1.66B
Long-Term Investments	15.79B	15.73B	16.39B	16.21B	15.05B	14.57B	15.1B	14.11B	14.14B	14.41B	14.23B	15.3B	14.2B	14.39B	14.63B	14.94B	13.78B	13.47B
Other Long-Term Assets	85.49M	36.71M	33.53M	42.79M	27.55M	4.49M	6.52M	20.21M	29.41M	28.03M	29.63M	30.61M	33.41M	3.87M	4.14M	4.51M	5.96M	7.14M
Receivables	27.74M	23.79M	26.96M	24.9M	23.58M	22.23M	22.41M	37.91M	35.23M	38.44M	36.6M	34.84M	35.35M	65.81M	68.31M	73.5M	44.84M	39.99M
Inventory	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Assets	4.45M	3.08M	4.19M	4.97M	2.29M	5.01M	18.04M	6.78M	10.22M	4.57M	90.52M	90.52M	67.12M	5.39M	6.63M	8.95M	12.1M	6.66M
Total Current Assets	1.52B	1.84B	1.8B	1.79B	2.58B	1.56B	1.27B	1.73B	2.95B	2.63B	2.55B	2.34B	3.5B	2.98B	2.88B	2.78B	2.71B	2.42B
Property-Plant & Equipment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Goodwill & Intangibles	924.63M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	5.67M	11.47M	17.26M	23M
Total Long-Term Assets	16.8B	15.77B	16.42B	16.25B	15.08B	14.57B	15.11B	14.13B	14.17B	14.44B	14.26B	15.33B	14.24B	14.4B	14.64B	14.96B	13.81B	13.5B
Total Assets	18.32B	17.61B	18.22B	18.04B	17.66B	16.13B	16.38B	15.86B	17.12B	17.07B	16.81B	17.67B	17.74B	17.38B	17.52B	17.73B	16.51B	15.91B
Account Payables	20.21M	37.63M	13.37M	22.05M	23.42M	11.55M	15.16M	13.63M	5.81M	6.66M	7.91M	16.11M	12.18M	6.66M	5.62M	9.19M	9.39M	8.27M
Deferred Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Short-Term Debt	999.44M	998.61M	997.77M	996.94M	n/a	n/a	n/a	n/a	999.37M	998.44M	997.51M	996.58M	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Liabilities	3.08M	18.6M	68.6M	31.2M	97.49M	9.02M	11.38M	n/a	n/a	n/a	12.4M	n/a	n/a	n/a	n/a	n/a	4.31M	n/a
Total Current Liabilities	1.21B	1.18B	1.25B	1.17B	275.7M	124.57M	161.38M	127.93M	1.17B	1.12B	1.17B	1.13B	182.33M	135.87M	171.25M	255.06M	283.99M	255.98M
Long-Term Debt	7B	6.62B	6.61B	6.61B	7.6B	6.14B	6.14B	6.13B	6.13B	6.12B	6.12B	6.11B	7.11B	7.1B	7.1B	7.09B	5.83B	5.82B
Other Long-Term Liabilities	610.47M	17.9M	12.08M	5.58M	27.04M	3.22M	900K	11.3M	8.5M	12.3M	2.5M	9.9M	43.7M	n/a	n/a	n/a	n/a	n/a
Total Long-Term Liabilities	7.61B	6.64B	6.63B	6.62B	7.63B	6.14B	6.14B	6.14B	6.14B	6.14B	6.12B	6.12B	7.15B	7.1B	7.1B	7.09B	5.83B	5.82B
Total Liabilities	8.82B	7.82B	7.88B	7.78B	7.9B	6.27B	6.3B	6.27B	7.31B	7.25B	7.29B	7.26B	7.33B	7.24B	7.27B	7.35B	6.11B	6.08B
Total Debt	8B	7.62B	7.61B	7.61B	7.6B	6.14B	6.14B	6.13B	7.13B	7.12B	7.12B	7.11B	7.11B	7.1B	7.1B	7.09B	5.83B	5.82B
Common Stock	107K	106K	108K	108K	108K	108K	108K	108K	109K	108K	107K	107K	107K	106K	106K	106K	105K	102K
Retained Earnings	2.22B	2.48B	2.85B	2.76B	2.38B	2.43B	2.52B	2.13B	2.25B	2.22B	1.96B	2.5B	2.45B	2.22B	2.26B	2.32B	2.29B	1.92B
Comprehensive Income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	16.9M	13.18M	12.3M	16.49M	20.55M	28.67M	29.45M
Shareholders Equity	6.35B	6.69B	6.95B	6.87B	6.48B	6.5B	6.53B	6.14B	6.28B	5.95B	5.63B	6.15B	6.03B	5.78B	5.78B	5.79B	5.73B	4.88B
Total Investments	16.65B	16.46B	17.23B	17.02B	15.84B	15.26B	15.86B	14.85B	14.87B	15.03B	14.95B	16.53B	15.5B	15.51B	15.89B	15.83B	15.29B	15.13B